Last updated on July 2017

Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease


Brief description of study

The purpose of this research study is to test the safety and efficacy of a drug called Plerixafor. Plerixafor is approved by the US FDA for use in increasing blood stem cell counts before collection in cancer patients. It is not yet approved for patients with sickle cell disease. The investigators want to find out if Plerixafor can be used to increase cell counts in patients with sickle cell disease.

Clinical Study Identifier: NCT02193191

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Farid Boulad, MD

Memorial Sloan Kettering Cancer Center
New York, NY United States
  Connect »

Tsiporah Shore, MD

Weill Cornell Medical College
New York, NY United States
  Connect »